Akebia Therapeutics, Inc. AX9.F Stock
Akebia Therapeutics, Inc. Price Chart
Akebia Therapeutics, Inc. AX9.F Financial and Trading Overview
| Akebia Therapeutics, Inc. stock price | 1.01 EUR |
| Previous Close | 1.08 EUR |
| Open | 1.02 EUR |
| Bid | 1.03 EUR x 30000 |
| Ask | 1.05 EUR x 30000 |
| Day's Range | 1.02 - 1.02 EUR |
| 52 Week Range | 0.22 - 1.32 EUR |
| Volume | 100 EUR |
| Avg. Volume | 283 EUR |
| Market Cap | 190.02M EUR |
| Beta (5Y Monthly) | 0.724295 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.54 EUR |
AX9.F Valuation Measures
| Enterprise Value | 240.48M EUR |
| Trailing P/E | N/A |
| Forward P/E | -1.3102564 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.70109725 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 0.887 |
| Enterprise Value/EBITDA | 7.2 |
Trading Information
Akebia Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.724295 |
| 52-Week Change | 307.43% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.32 EUR |
| 52 Week Low | 0.22 EUR |
| 50-Day Moving Average | 0.83 EUR |
| 200-Day Moving Average | 0.56 EUR |
AX9.F Share Statistics
| Avg. Volume (3 month) | 283 EUR |
| Avg. Daily Volume (10-Days) | 1.01K EUR |
| Shares Outstanding | 185.93M |
| Float | 168M |
| Short Ratio | N/A |
| % Held by Insiders | 1.27% |
| % Held by Institutions | 29.14% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -20.79% |
| Operating Margin (ttm) | -1.57% |
| Gross Margin | 55.84% |
| EBITDA Margin | 12.32% |
Management Effectiveness
| Return on Assets (ttm) | -0.65% |
| Return on Equity (ttm) | -958.14% |
Income Statement
| Revenue (ttm) | 271.03M EUR |
| Revenue Per Share (ttm) | 1.47 EUR |
| Quarterly Revenue Growth (yoy) | -35.00000000000000000000000000000000% |
| Gross Profit (ttm) | 141.8M EUR |
| EBITDA | 33.4M EUR |
| Net Income Avi to Common (ttm) | -56358000 EUR |
| Diluted EPS (ttm) | -0.28 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 56.95M EUR |
| Total Cash Per Share (mrq) | 0.31 EUR |
| Total Debt (mrq) | 82.87M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.455 |
| Book Value Per Share (mrq) | -0.077 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -69072000 EUR |
| Levered Free Cash Flow (ttm) | 10.03M EUR |
Profile of Akebia Therapeutics, Inc.
| Country | Germany |
| State | MA |
| City | Cambridge |
| Address | 245 First Street |
| ZIP | 02142 |
| Phone | 617 871 2098 |
| Website | https://www.akebia.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 204 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Q&A For Akebia Therapeutics, Inc. Stock
What is a current AX9.F stock price?
Akebia Therapeutics, Inc. AX9.F stock price today per share is 1.01 EUR.
How to purchase Akebia Therapeutics, Inc. stock?
You can buy AX9.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Akebia Therapeutics, Inc.?
The stock symbol or ticker of Akebia Therapeutics, Inc. is AX9.F.
Which industry does the Akebia Therapeutics, Inc. company belong to?
The Akebia Therapeutics, Inc. industry is Biotechnology.
How many shares does Akebia Therapeutics, Inc. have in circulation?
The max supply of Akebia Therapeutics, Inc. shares is 220.14M.
What is Akebia Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Akebia Therapeutics, Inc. PE Ratio is now.
What was Akebia Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Akebia Therapeutics, Inc. EPS is -0.2 EUR over the trailing 12 months.
Which sector does the Akebia Therapeutics, Inc. company belong to?
The Akebia Therapeutics, Inc. sector is Healthcare.